Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IFCT

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: IFCT. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-002805-23 Sponsor Protocol Number: IFCT-1804 Start Date*: 2020-01-07
    Sponsor Name:IFCT
    Full Title: A Phase II, multi-centre study, to evaluate the efficacy and safety of osimertinib treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metasta...
    Medical condition: EGFR-mutated Non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    22.0 10018065 - General disorders and administration site conditions 10071975 EGFR gene mutation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004475-75 Sponsor Protocol Number: IFCT-1501 Start Date*: 2016-02-08
    Sponsor Name:IFCT
    Full Title: A randomized phase II study evaluating efficacy and safety of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Malignant Pleural Mesothelioma (MPM) ...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000092-16 Sponsor Protocol Number: IFCT-GFPC-1101 Start Date*: 2017-11-30
    Sponsor Name:IFCT
    Full Title: Phase III study evaluating two strategies of maintenance, one with pemetrexed in continuous strategy and one according to the response of induction chemotherapy, in non squamous non small cell lung...
    Medical condition: Advanced non squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004742-42 Sponsor Protocol Number: IFCT-1802 Start Date*: 2019-08-29
    Sponsor Name:IFCT
    Full Title: A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 t...
    Medical condition: Patient with a non small cell lung cancer and a poor general status
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.1 100000004867 10057364 Reduced general condition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001849-15 Sponsor Protocol Number: IFCT-1601 Start Date*: 2016-08-10
    Sponsor Name:IFCT
    Full Title: A PHASE II PROSPECTIVE IMMUNE NEOADJUVANT THERAPY STUDY OF DURVALUMAB (MEDI4736) IN EARLY STAGE NON-SMALL CELL LUNG CANCER
    Medical condition: Stage IB (> 4 cm), II Non Small Cell Lung Cancer resectable
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-002540-33 Sponsor Protocol Number: IFCT-1701 Start Date*: 2017-12-15
    Sponsor Name:IFCT
    Full Title: A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small C...
    Medical condition: PD-L1 positive stage IV Non Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2012-002647-18 Sponsor Protocol Number: IFCT-1102 Start Date*: 2017-10-13
    Sponsor Name:IFCT
    Full Title: phase II study evaluating the interest of the re-introduction of pemetrexed and platinum (cisplatin or carboplatin) with prolonged angiogenic blocking by bevacizumab in non squamous non small cell ...
    Medical condition: Advanced stage non squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025062 Lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003506-11 Sponsor Protocol Number: IFCT-1703 Start Date*: 2019-01-23
    Sponsor Name:IFCT
    Full Title: Phase II trial of trastuzumab in combination with pertuzumab in pretreated patients with non-small cell lung cancer (NSCLC) harboring a Her2 mutation and receiving docetaxel
    Medical condition: Non small cell lung cancer with a Her2 mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    23.0 10010331 - Congenital, familial and genetic disorders 10075653 HER2 gene amplification PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004621-24 Sponsor Protocol Number: IFCT-1904 Start Date*: 2020-11-18
    Sponsor Name:IFCT
    Full Title: A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
    Medical condition: BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    22.0 10022891 - Investigations 10075676 BRAF V600E mutation positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002230-37 Sponsor Protocol Number: IFCT-1902 Start Date*: 2019-09-16
    Sponsor Name:IFCT
    Full Title: A phase II non-randomized, single group assignment, open-label, multicenter study of efficacy and safety of lORlatinib (PF-06463922) monotherapy after failure of first-line second-generation ALK ki...
    Medical condition: advanced ALK-positive non-small cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004524-38 Sponsor Protocol Number: IFCT-1103 Start Date*: 2013-01-31
    Sponsor Name:IFCT
    Full Title: Phase III study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd line of treatment of non squamous Non Small Cells Lung Cancer
    Medical condition: Non squamous non small cell lung cancer of advanced stage
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025062 Lung cancer stage IV LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003796-22 Sponsor Protocol Number: IFCT-1602 Start Date*: 2017-09-22
    Sponsor Name:IFCT
    Full Title: Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial
    Medical condition: Advanced non small cell lung cancer in VIH+ patient
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    20.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005520-15 Sponsor Protocol Number: IFCT-1201 Start Date*: 2013-02-28
    Sponsor Name:IFCT
    Full Title: Phase III study comparing maintenance by pemetrexed or gemcitabine to surveillance in elderly patient (≥ 70 year old) with advanced Non Small Cell Lung Cancer controlled by induction chemotherapy
    Medical condition: Advanced Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-006044-27 Sponsor Protocol Number: IFCT-2103 Start Date*: 2022-02-10
    Sponsor Name:IFCT
    Full Title: A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pe...
    Medical condition: Advanced Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003795-49 Sponsor Protocol Number: IFCT-1603 Start Date*: 2016-12-16
    Sponsor Name:IFCT
    Full Title: A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung can...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003390-15 Sponsor Protocol Number: IFCT-1503 Start Date*: 2015-11-20
    Sponsor Name:IFCT
    Full Title: Phase II study evaluating the combination of cetuximab with afatinib as first-line treatment for patients with EGFR mutated Non Small Cell Lung Cancer
    Medical condition: Advanced Non Small Cell Lung Cancer with EGFR mutation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004466-19 Sponsor Protocol Number: IFCT-2003 Start Date*: 2021-01-07
    Sponsor Name:IFCT
    Full Title: A phase II single-group assignment, multicenter study of efficacy and safety of lorlatinib monotherapy after failure of first-line tyrosine kinase inhibitor in patients with advanced ROS1-positive ...
    Medical condition: advanced ROS1-positive non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003571-11 Sponsor Protocol Number: IFCT-1003 Start Date*: 2018-11-30
    Sponsor Name:IFCT
    Full Title: A randomised, phase II trial to evaluate a treatment with Tyrosine Kinase Inhibitor of Epidermal Growth Factor (EGFR-TKI) versus EGFR-TKI associated with an anti-estrogen treatment (fulvestrant) in...
    Medical condition: advanced stage non squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002567-22 Sponsor Protocol Number: IFCT-2101 Start Date*: 2022-01-10
    Sponsor Name:IFCT
    Full Title: A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in pati...
    Medical condition: Advanced ALK-positive non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012412-41 Sponsor Protocol Number: IFCT-0803 Start Date*: 2010-01-11
    Sponsor Name:IFCT
    Full Title: Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellul...
    Medical condition: Stage III Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025052 Lung cancer non-small cell stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 21:55:20 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA